Compare Plby Group Inc (PLBY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs TransMedics Group Inc — how do they compare? Plby Group Inc trades at $0.98 (market cap $118.21M), while TransMedics Group Inc trades at $78.32 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 23.2× Plby Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and TransMedics Group Inc for 24 Days on average.
| PLBY | TMDX | |
|---|---|---|
Market Cap | $118.21M | $2.74B |
Volume | 919,783 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $150.42 |
52-Week Low | $0.99 | $61.99 |
Typical Hold Time | 24 Days | 24 Days |
Enterprise Value | $263.80M | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $0.97, down 4.5% today, with a bearish technical outlook despite analyst optimism. The company shows improving fundamentals with revenue stabilizing around $120M and narrowing losses, though it remains unprofitable with negative equity. Recent leadership appointments signal strategic focus on brand growth and licensing expansion.
The stock presents a turnaround opportunity with strong analyst support (75% buy ratings) but carries significant risk from high debt levels and negative shareholder equity. Near-term catalysts depend on execution of the media and experiences strategy, while competitive pressures and cash flow volatility remain concerns.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
